De Novo Movement Disorders and COVID‐19: Exploring the Interface

Ghosh, Ritwik; Biswas, Uttam; Roy, Dipayan; Pandit, Alak; Lahiri, Durjoy; Ray, Biman Kanti; Benito‐León, Julián

BACKGROUND: Neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are being widely documented. However, movement disorders in the setting of 2019 coronavirus infectious disease (COVID‐19) have been a strikingly less discussed topic. OBJECTIVES: To summarize available pieces of evidence documenting de novo movement disorders in COVID‐19. METHODS: We used the existing PRISMA consensus statement. Data were collected from PubMed, EMBASE, Web of Science, and Scopus databases up to the 29th January, 2021, using pre‐specified searching strategies. RESULTS: Twenty‐two articles were selected for the qualitative synthesis. Among these, a total of 52 patients with de novo movement disorders were reported. Most of these had myoclonus, ataxia, tremor or a combination of these, while three had parkinsonism and one a functional disorder. In general, they were managed successfully by intravenous immunoglobulin or steroids. Some cases, primarily with myoclonus, could be ascribed to medication exposures, metabolic disturbances or severe hypoxia, meanwhile others to a post‐or para‐infectious immune‐mediated mechanism. SARS‐CoV‐2 could also invade the central nervous system, through vascular or retrograde axonal pathways, and cause movement disorders by two primary mechanisms. Firstly, through the downregulation of angiotensin‐converting enzyme 2 receptors, resulting in the imbalance of dopamine and norepinephrine; and secondly, the virus could cause cellular vacuolation, demyelination and gliosis, leading to encephalitis and associated movement disorders. CONCLUSION: De novo movement disorders are scantly reported in COVID‐19. The links between SARS‐CoV‐2 and movement disorders are not yet established. However, we should closely monitor COVID‐19 survivors for the possibility of post‐COVID movement disorders.